EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

W. J. Fokkens; An-Sofie Viskens; Vibeke Backer; Diego Conti; Eugenio de Corso; Philippe Gevaert; Glenis K. Scadding; Martin Wagemann; Manuel Bernal Sprekelsen; Adam Chaker; Enrico Heffler; Joseph K. Han; Elizabeth Van Staeyen; Claire Hopkins; Joaquim Mullol; Anju Peters; Sietze Reitsma; Brent A. Senior; Peter W. Hellings

doi:https://doi.org/10.4193/Rhin22.489

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

W. J. Fokkens, An-Sofie Viskens, Vibeke Backer, Diego Conti, Eugenio de Corso, Philippe Gevaert, Glenis K. Scadding, Martin Wagemann, Manuel Bernal Sprekelsen, Adam Chaker, Enrico Heffler, Joseph K. Han, Elizabeth Van Staeyen, Claire Hopkins, Joaquim Mullol, Anju Peters, Sietze Reitsma, Brent A. Senior, Peter W. Hellings

Research output: Contribution to journal › Article › Academic › peer-review

45 Citations (Scopus)

Abstract

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.

Original language	English
Pages (from-to)	194-202
Number of pages	9
Journal	Rhinology
Volume	61
Issue number	3
DOIs	https://doi.org/10.4193/Rhin22.489
Publication status	Published - 2023

Keywords

Chronic rhinosinusitis
biologics
biomarkers
indication
nasal polyps
patient selection
thera-peutic response
type 2 inflammation

Access to Document

https://doi.org/10.4193/Rhin22.489

Cite this

Fokkens, W. J., Viskens, A.-S., Backer, V., Conti, D., de Corso, E., Gevaert, P., Scadding, G. K., Wagemann, M., Sprekelsen, M. B., Chaker, A., Heffler, E., Han, J. K., Staeyen, E. V., Hopkins, C., Mullol, J., Peters, A., Reitsma, S., Senior, B. A., & Hellings, P. W. (2023). EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology, 61(3), 194-202. https://doi.org/10.4193/Rhin22.489

@article{74f28bce82974b35ac6db09f1a9c44e3,

title = "EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023",

abstract = "Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.",

keywords = "Chronic rhinosinusitis, biologics, biomarkers, indication, nasal polyps, patient selection, thera-peutic response, type 2 inflammation",

author = "Fokkens, {W. J.} and An-Sofie Viskens and Vibeke Backer and Diego Conti and {de Corso}, Eugenio and Philippe Gevaert and Scadding, {Glenis K.} and Martin Wagemann and Sprekelsen, {Manuel Bernal} and Adam Chaker and Enrico Heffler and Han, {Joseph K.} and Staeyen, {Elizabeth Van} and Claire Hopkins and Joaquim Mullol and Anju Peters and Sietze Reitsma and Senior, {Brent A.} and Hellings, {Peter W.}",

year = "2023",

doi = "https://doi.org/10.4193/Rhin22.489",

language = "English",

volume = "61",

pages = "194--202",

journal = "Rhinology",

issn = "0300-0729",

publisher = "University Hospital Utrecht",

number = "3",

}

Fokkens, WJ, Viskens, A-S, Backer, V, Conti, D, de Corso, E, Gevaert, P, Scadding, GK, Wagemann, M, Sprekelsen, MB, Chaker, A, Heffler, E, Han, JK, Staeyen, EV, Hopkins, C, Mullol, J, Peters, A, Reitsma, S, Senior, BA & Hellings, PW 2023, 'EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023', Rhinology, vol. 61, no. 3, pp. 194-202. https://doi.org/10.4193/Rhin22.489

TY - JOUR

T1 - EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

AU - Fokkens, W. J.

AU - Viskens, An-Sofie

AU - Backer, Vibeke

AU - Conti, Diego

AU - de Corso, Eugenio

AU - Gevaert, Philippe

AU - Scadding, Glenis K.

AU - Wagemann, Martin

AU - Sprekelsen, Manuel Bernal

AU - Chaker, Adam

AU - Heffler, Enrico

AU - Han, Joseph K.

AU - Staeyen, Elizabeth Van

AU - Hopkins, Claire

AU - Mullol, Joaquim

AU - Peters, Anju

AU - Reitsma, Sietze

AU - Senior, Brent A.

AU - Hellings, Peter W.

PY - 2023

Y1 - 2023

N2 - Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.

AB - Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.

KW - Chronic rhinosinusitis

KW - biologics

KW - biomarkers

KW - indication

KW - nasal polyps

KW - patient selection

KW - thera-peutic response

KW - type 2 inflammation

UR - http://www.scopus.com/inward/record.url?scp=85162822635&partnerID=8YFLogxK

U2 - https://doi.org/10.4193/Rhin22.489

DO - https://doi.org/10.4193/Rhin22.489

M3 - Article

C2 - 36999780

SN - 0300-0729

VL - 61

SP - 194

EP - 202

JO - Rhinology

JF - Rhinology

IS - 3

ER -

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Abstract

Keywords

Access to Document

Other files and links

Cite this